Tsui, Edmund, Sella, Ruti, Tham, Vivien, Kong, Alan W., McClean, Esmeralda, Goren, Lee, Bahar, Irit, Cherian, Nina, Ramirez, Joana, Hughes, Reginald E., Privratsky, Joseph K., Onclinx, Tania, Feit-Leichman, Rachel, Cheng, Angel, Molina, Iliana, Kim, Phillip, Yu, Carol, Ruder, Kevin, Tan, Alexander, Chen, Cindi, Liu, YuHeng, Abraham, Thomas, Hinterwirth, Armin, Zhong, Lina, Porco, Travis C., Lietman, Thomas M., Seitzman, Gerami D., and Doan, Thuy
IMPORTANCE: Acute infectious conjunctivitis is a common ocular condition with major public health consequences. OBJECTIVE: To assess regional variations and microbial etiologies of acute infectious conjunctivitis to guide treatment. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, patients with presumed acute infectious conjunctivitis were enrolled in the study at 5 sites (Honolulu, Hawaii; Los Angeles, San Francisco, and San Diego, California; and Petah-Tikva, Israel) from March 2021 to March 2023. Patients with allergic or toxic conjunctivitis were excluded. MAIN OUTCOMES AND MEASURES: Pathogens were identified by unbiased RNA deep sequencing. RESULTS: In all, 52 patients (mean [range] age, 48 [7-80] years; 31 females [60%]) were enrolled at 5 sites (6 patients from Honolulu, 9 from San Diego, 11 from Los Angeles, 13 from San Francisco, and 13 from Petah-Tikva). RNA deep sequencing detected human adenovirus species D in one-quarter of patients (13 of 52). A wide range of pathogens, including human coronavirus 229E, SARS-CoV-2, and herpes simplex virus type 1, was also identified, as well as several bacteria and fungi. Moreover, 62% (32 of 52) of patients presented with purulent discharge, while only 8% (4 of 52) of patients had confirmed bacterial pathogens. CONCLUSION AND RELEVANCE: In this cross-sectional study, pathogens associated with acute infectious conjunctivitis varied between all 5 sites in the US and Israel. Purulent discharge was a common presenting sign in this study, with a low specificity for bacteria-associated conjunctivitis, suggesting that further diagnostic workup may be necessary to inform antibiotic stewardship. Additional research on cost-effectiveness of using RNA deep sequencing is needed to ascertain whether it is better to monitor patients clinically until resolution of disease.